Ironwood Gears Up For Phase III China Linaclotide Trial; Eyes On South America And Other Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Taking an unusually global perspective for a clinical-stage biotech, Ironwood Pharmaceuticals has plans to undertake clinical trials of its lead gastrointestinal drug, linaclotide, in China, Brazil and other emerging markets, then seek regional partners.
You may also be interested in...
Deals Of The Week: Pfizer/NextWave, Genzyme/Alnylam, AstraZeneca/Ironwood
Two Western big pharmas struck back-to-back deals this week with two U.S. biopharmas and will bring their innovative drugs to Asia without a local partner. The details of the deals are different, but both signal a willingness on the part of biopharmas to partner with experienced, feet-on-the-ground Western companies as a route into emerging Asian markets, though they’ll still need to find a local partner down the road.
AstraZeneca And Ironwood Link Up To Bring Linaclotide To China
Ironwood has signed AstraZeneca as its partner to develop and commercialize the irritable bowel syndrome drug linaclotide in China, though a Phase III trial has yet to start; Ironwood also announced it will commercialize AstraZeneca’s Nexium in the U.S.
AstraZeneca And Ironwood Link Up To Bring Linaclotide To China
Ironwood has signed AstraZeneca as its partner to develop and commercialize the irritable bowel syndrome drug linaclotide in China, though a Phase III trial has yet to start; Ironwood also announced it will commercialize AstraZeneca’s Nexium in the U.S.